PDF(Pubmed)
Abstract：
BACKGROUND: Understanding the association between hypertension prevalence and socioeconomic and behavioral variables during a pandemic is essential, and this analysis should extend beyond short-term trends.
OBJECTIVE: This study aims to examine long-term trends in the prevalence of participants diagnosed with and receiving treatment for hypertension, using data collected by a nationally representative survey from 2009 to 2022, which includes the COVID-19 pandemic era.
METHODS: A nationwide, population-based, cross-sectional study used data collected from the South Korea Community Health Survey between 2009 and 2022. The study sample comprised 3,208,710 Korean adults over a period of 14 years. We aimed to assess trends in the prevalence of participants diagnosed with and receiving treatment for hypertension in the national population from 2009 to 2022, with a specific focus on the COVID-19 pandemic, using weighted linear regression models.
RESULTS: Among the included 3,072,546 Korean adults, 794,239 (25.85%) were aged 19-39 years, 1,179,388 (38.38%) were aged 40-59 years; 948,097 (30.86%) were aged 60-79 years, and 150,822 (4.91%) were aged 80 years or older. A total of 1,426,379 (46.42%) were men; 761,896 (24.80%) and 712,264 (23.18%) were diagnosed with and received treatment for hypertension, respectively. Although the overall prevalence over the 14-year period increased, the upward trends of patients diagnosed with and receiving treatment for hypertension decreased during the COVID-19 pandemic era compared with the prepandemic era (β difference for trend during vs before the pandemic -.101, 95% CI -0.107 to -0.094 vs -.133, 95% CI -0.140 to -0.127). Notably, the trends in prevalence during the pandemic were less pronounced in subgroups of older adults (≥60 years old) and individuals with higher alcohol consumption (≥5 days/month).
CONCLUSIONS: This nationwide representative study found that the national prevalence of participants diagnosed with and receiving treatment for hypertension increased during the prepandemic era. However, there was a marked decrease in these trends during the prepandemic era, compared with the pandemic era, particularly among specific subgroups at increased risk of negative outcomes. Future studies are needed to evaluate the factors associated with changes in the prevalence of hypertension during the COVID-19 pandemic.
OBJECTIVE: This study aims to examine long-term trends in the prevalence of participants diagnosed with and receiving treatment for hypertension, using data collected by a nationally representative survey from 2009 to 2022, which includes the COVID-19 pandemic era.
METHODS: A nationwide, population-based, cross-sectional study used data collected from the South Korea Community Health Survey between 2009 and 2022. The study sample comprised 3,208,710 Korean adults over a period of 14 years. We aimed to assess trends in the prevalence of participants diagnosed with and receiving treatment for hypertension in the national population from 2009 to 2022, with a specific focus on the COVID-19 pandemic, using weighted linear regression models.
RESULTS: Among the included 3,072,546 Korean adults, 794,239 (25.85%) were aged 19-39 years, 1,179,388 (38.38%) were aged 40-59 years; 948,097 (30.86%) were aged 60-79 years, and 150,822 (4.91%) were aged 80 years or older. A total of 1,426,379 (46.42%) were men; 761,896 (24.80%) and 712,264 (23.18%) were diagnosed with and received treatment for hypertension, respectively. Although the overall prevalence over the 14-year period increased, the upward trends of patients diagnosed with and receiving treatment for hypertension decreased during the COVID-19 pandemic era compared with the prepandemic era (β difference for trend during vs before the pandemic -.101, 95% CI -0.107 to -0.094 vs -.133, 95% CI -0.140 to -0.127). Notably, the trends in prevalence during the pandemic were less pronounced in subgroups of older adults (≥60 years old) and individuals with higher alcohol consumption (≥5 days/month).
CONCLUSIONS: This nationwide representative study found that the national prevalence of participants diagnosed with and receiving treatment for hypertension increased during the prepandemic era. However, there was a marked decrease in these trends during the prepandemic era, compared with the pandemic era, particularly among specific subgroups at increased risk of negative outcomes. Future studies are needed to evaluate the factors associated with changes in the prevalence of hypertension during the COVID-19 pandemic.
摘要：
背景：了解大流行期间高血压患病率与社会经济和行为变量之间的关联至关重要，这种分析应该超越短期趋势。
目的：本研究旨在研究被诊断为高血压并接受高血压治疗的参与者的患病率的长期趋势。使用2009年至2022年全国代表性调查收集的数据，其中包括COVID-19大流行时期。
方法：全国范围内，以人口为基础,横断面研究使用了2009年至2022年韩国社区健康调查收集的数据.研究样本包括3,208,710名韩国成年人，历时14年。我们旨在评估2009年至2022年全国人群中被诊断为高血压并接受高血压治疗的参与者的患病率趋势，特别关注COVID-19大流行，使用加权线性回归模型。
结果：在包括的3,072,546名韩国成年人中，794,239（25.85%）年龄在19-39岁之间，1,179,388（38.38%）年龄在40-59岁；948,097（30.86%）年龄在60-79岁，和150,822（4.91％）年龄在80岁或以上。共有1,426,379人(46.42%)为男性;761,896人(24.80%)和712,264人(23.18%)被诊断为高血压并接受治疗,分别。尽管14年期间的总体患病率有所增加，与流行前相比，在COVID-19大流行时期，诊断和接受高血压治疗的患者的上升趋势下降(大流行期间与大流行前的趋势差异-0.101，95%CI-0.107~-0.094vs.133，95%CI-0.140~-0.127)。值得注意的是,大流行期间的患病率趋势在老年人(≥60岁)和饮酒较高(≥5日/月)的个体亚组中不太明显.
结论：这项全国性的代表性研究发现，全国范围内被诊断为高血压并接受高血压治疗的参与者的患病率在大流行时期增加。然而,在大流行时期，这些趋势明显下降，与大流行时代相比，特别是在负面结果风险增加的特定亚组中。未来的研究需要评估与COVID-19大流行期间高血压患病率变化相关的因素。
目的：本研究旨在研究被诊断为高血压并接受高血压治疗的参与者的患病率的长期趋势。使用2009年至2022年全国代表性调查收集的数据，其中包括COVID-19大流行时期。
方法：全国范围内，以人口为基础,横断面研究使用了2009年至2022年韩国社区健康调查收集的数据.研究样本包括3,208,710名韩国成年人，历时14年。我们旨在评估2009年至2022年全国人群中被诊断为高血压并接受高血压治疗的参与者的患病率趋势，特别关注COVID-19大流行，使用加权线性回归模型。
结果：在包括的3,072,546名韩国成年人中，794,239（25.85%）年龄在19-39岁之间，1,179,388（38.38%）年龄在40-59岁；948,097（30.86%）年龄在60-79岁，和150,822（4.91％）年龄在80岁或以上。共有1,426,379人(46.42%)为男性;761,896人(24.80%)和712,264人(23.18%)被诊断为高血压并接受治疗,分别。尽管14年期间的总体患病率有所增加，与流行前相比，在COVID-19大流行时期，诊断和接受高血压治疗的患者的上升趋势下降(大流行期间与大流行前的趋势差异-0.101，95%CI-0.107~-0.094vs.133，95%CI-0.140~-0.127)。值得注意的是,大流行期间的患病率趋势在老年人(≥60岁)和饮酒较高(≥5日/月)的个体亚组中不太明显.
结论：这项全国性的代表性研究发现，全国范围内被诊断为高血压并接受高血压治疗的参与者的患病率在大流行时期增加。然而,在大流行时期，这些趋势明显下降，与大流行时代相比，特别是在负面结果风险增加的特定亚组中。未来的研究需要评估与COVID-19大流行期间高血压患病率变化相关的因素。
